Randall Stanicky
Stock Analyst at RBC Capital
(2.30)
# 2,457
Out of 4,683 analysts
32
Total ratings
62.5%
Success rate
5.22%
Average return
Main Sectors:
Stocks Rated by Randall Stanicky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $129 → $135 | $181.50 | -25.62% | 10 | Feb 4, 2021 | |
| PRGO Perrigo Company | Downgrades: Sector Perform | $59 → $49 | $28.42 | +72.41% | 8 | Jan 6, 2021 | |
| PFE Pfizer | Downgrades: Sector Perform | $43 → $42 | $25.56 | +64.32% | 3 | Dec 16, 2020 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $170 → $180 | $121.64 | +47.98% | 2 | Nov 3, 2020 | |
| MRK Merck & Co. | Maintains: Sector Perform | $92 → $89 | $101.85 | -12.62% | 1 | Apr 1, 2020 | |
| AMRX Amneal Pharmaceuticals | Maintains: Sector Perform | $3 → $4 | $8.53 | -53.11% | 3 | Jan 2, 2020 | |
| OPTN OptiNose | Initiates: Outperform | $33 | $0.54 | +6,011.11% | 1 | Nov 7, 2017 | |
| TEVA Teva Pharmaceutical | Downgrades: Underperform | n/a | $17.53 | - | 3 | Aug 4, 2017 | |
| PCRX Pacira BioSciences | Initiates: Outperform | $58 | $16.68 | +247.72% | 1 | Apr 13, 2017 |
AbbVie
Feb 4, 2021
Maintains: Outperform
Price Target: $129 → $135
Current: $181.50
Upside: -25.62%
Perrigo Company
Jan 6, 2021
Downgrades: Sector Perform
Price Target: $59 → $49
Current: $28.42
Upside: +72.41%
Pfizer
Dec 16, 2020
Downgrades: Sector Perform
Price Target: $43 → $42
Current: $25.56
Upside: +64.32%
Jazz Pharmaceuticals
Nov 3, 2020
Maintains: Outperform
Price Target: $170 → $180
Current: $121.64
Upside: +47.98%
Merck & Co.
Apr 1, 2020
Maintains: Sector Perform
Price Target: $92 → $89
Current: $101.85
Upside: -12.62%
Amneal Pharmaceuticals
Jan 2, 2020
Maintains: Sector Perform
Price Target: $3 → $4
Current: $8.53
Upside: -53.11%
OptiNose
Nov 7, 2017
Initiates: Outperform
Price Target: $33
Current: $0.54
Upside: +6,011.11%
Teva Pharmaceutical
Aug 4, 2017
Downgrades: Underperform
Price Target: n/a
Current: $17.53
Upside: -
Pacira BioSciences
Apr 13, 2017
Initiates: Outperform
Price Target: $58
Current: $16.68
Upside: +247.72%